Carasent AB AI Stock Analysis
Want to see SE:CARA full AI Analyst Report?
Carasent AB (CARA) AI Stock Analysis
Carasent AB
(Nasdaq OMX AB:CARA)
Carasent's overall score of 71 reflects a company that has successfully pivoted to profitable, cash-generative growth, which is the most significant positive factor. The financial turnaround, underscored by strong cash flow and a debt-free balance sheet, provides a solid foundation. The positive guidance and strong backlog from the earnings call further support the outlook. These strengths are partially offset by a high P/E ratio, which already discounts much of the good news, and a technical picture that, while bullish, is approaching overbought levels. The main operational risks to monitor are the gross margin trend and the execution of the delayed German product launch.
Carasent AB (CARA) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 1.70B
- Dividend Yield
- ―
- Average Volume (3M)
- 93.23K
- Price to Earnings (P/E)
- 44.0
- Beta (1Y)
- 0.22
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Sweden
- Employees
- 231
- Sector
- General
- Sector Strength
- 55
- Industry
- Software - Application
Carasent AB Business Overview & Revenue Model
Company Description
Carasent AB (publ) provides cloud based electronic health record (EHR) systems solutions and platform services for healthcare sector in Nordics and Germany. The company offers Webdoc, Webcur, Metodika, Ad Curis, Ad Opus, and Data-AL solutions. It als...
How the Company Makes Money
Carasent primarily makes money by selling access to its healthcare software products and related services to healthcare organizations. The core revenue model is typically based on recurring fees for software usage (e.g., subscriptions/SaaS-style lice...
Carasent AB Earnings Call Summary
The call was broadly positive, supported by 29% growth, 14% organic ARR growth, improving EBITDA margins, strong sales, healthy net retention, strong year-to-date cash flow and encouraging MedSum and Infosolutions momentum. The main challenges were Germany's delayed Webcur rollout and elevated churn, seasonally and comparably difficult Q4 conditions, planned near-term cost increases, and the slow pace of healthcare technology adoption. Highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management said it will continue to grow strongly, especially in Nordic, pick up the pace in Germany, push Webcur into the market in Q4, and maintain strong cost control; the majority of the backlog will be implemented in Q4, with the Webdoc part implemented within this year, Falck next year, and Frelsesarmeen a bit this year and a bit next year. Medsum’s new functionality is coming around Christmas, with the price staying at roughly SEK 750 per user and month, while MDR certification will require a couple of million in Q4; increased German sales and marketing, including three, four salespeople and other initiatives, will result in around SEK 3 million-SEK 4 million extra cost in the quarter compared to this one, with personnel costs increasing the cost base by a couple of million in Q1 and other effects mostly temporary. Infosolutions will have price increases by New Year and, if it is going according to plan, will next year be among the top companies in the group from a rule of 40 perspective.
Carasent AB Financial Statement Overview
Summary
Carasent demonstrates a strong financial turnaround. Profitability has been restored with a 12% net margin in the TTM period, and revenue growth is robust. The balance sheet is a fortress with minimal debt. Critically, cash flow generation has surged, with operating cash flow far exceeding net income, indicating high-quality earnings. The main concern is the gross margin compression to 69%.
Income Statement
65PositiveBalance Sheet
85Very PositiveCash Flow
70Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 389.84M | 343.82M | 266.90M | 243.98M | 195.26M | 137.13M |
| Gross Profit | 260.80M | 289.00M | 225.64M | 197.77M | 161.42M | 112.90M |
| EBITDA | 86.20M | 73.34M | 18.85M | 2.91M | 59.11M | 28.32M |
| Net Income | 39.53M | 34.67M | -40.97M | -46.45M | 31.17M | -148.00K |
Balance Sheet | ||||||
| Total Assets | 980.79M | 941.01M | 1.04B | 1.09B | 1.37B | 1.30B |
| Cash, Cash Equivalents and Short-Term Investments | 47.10M | 139.48M | 254.05M | 373.88M | 694.83M | 882.77M |
| Total Debt | 25.41M | 31.94M | 39.95M | 50.17M | 38.88M | 16.34M |
| Total Liabilities | 168.17M | 133.00M | 173.97M | 138.24M | 144.30M | 129.54M |
| Stockholders Equity | 812.62M | 808.00M | 865.73M | 955.41M | 1.23B | 1.17B |
Cash Flow | ||||||
| Free Cash Flow | 58.63M | -476.00K | -4.99M | -73.67M | -57.95M | -5.75M |
| Operating Cash Flow | 94.38M | 40.44M | 36.58M | -4.47M | 33.61M | 32.48M |
| Investing Cash Flow | -126.53M | -35.98M | -116.42M | -55.53M | -209.50M | -125.12M |
| Financing Cash Flow | -93.47M | -122.22M | -15.88M | -263.28M | -10.20M | 756.56M |
Carasent AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CARA, the sentiment is Negative. The current price of 25.20 is below the 20-day moving average (MA) of 26.19, below the 50-day MA of 26.46, and above the 200-day MA of 24.53, indicating a neutral trend. The MACD of -0.35 indicates Positive momentum. The RSI at 37.33 is Neutral, neither overbought nor oversold. The STOCH value of 13.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CARA.
Carasent AB Peers Comparison
Overall Rating
SE:LIME79Outperform
SE:UPSALE78Outperform
SE:VIT.B75Outperform
SE:CARA71Outperform
SE:ONEF60Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 79Outperform | SEK 3.44B | 27.96 | 32.20% | 1.75% | 8.57% | 17.98% | |
| 78Outperform | SEK 431.06M | 15.80 | ― | 8.49% | 11.34% | 40.60% | |
| 75Outperform | SEK 11.65B | 24.56 | 9.27% | 1.25% | 5.55% | 18.93% | |
| 71Outperform | SEK 1.68B | 44.02 | ― | ― | ― | ― | |
| 60Neutral | SEK 508.65M | -54.39 | ― | ― | 20.62% | 85.64% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:CARA | Carasent AB | 25.20 | -1.80 | -6.67% | |
| SE:DONE | 24Sevenoffice Scandinavia Ab | 5.81 | -0.24 | -3.97% | |
| SE:LIME | Lime Technologies AB | 257.50 | -49.80 | -16.20% | |
| SE:VIT.B | Vitec Software Group AB Class B | 292.00 | -6.44 | -2.16% | |
| SE:UPSALE | Upsales Technology AB | 25.60 | -3.78 | -12.86% | |
| SE:ONEF | Oneflow AB | 17.95 | -8.05 | -30.96% |
Carasent AB Corporate Events
Carasent Sets Nomination Committee Ahead of 2027 Annual General Meeting
Carasent AB has appointed its Nomination Committee for the 2027 Annual General Meeting, following instructions adopted at an Extraordinary General Meeting in 2024. The committee consists of three members representing the company’s largest shareholder...
Carasent Sets Webcast for Release of Q3 2026 Interim Results
Carasent AB announced that it will publish its interim report for the third quarter of 2026 on October 15 at 07:00 CEST. The company will follow the release with a webcast presentation of the results the same day at 08:00 CEST, offering stakeholders...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 16, 2026
